Elmiron Eye Damage Lawsuits

These lawsuits seek to hold the manufacturer accountable for the safety and quality of their product. Some of the most common side effects include vision loss, vision problems, and even maculopathy.

Class-action lawsuits filed

The plaintiffs allege that long term use of the drug caused severe visual problems. The lawsuit claims that the makers of Elmiron did not warn consumers about the dangers of the drug.

One of the major complaints in Elmiron eye damage lawsuits is that the drug makers failed to warn consumers about the potential for serious vision problems. In fact, according to the FDA, the label for the drug did not even mention that the risk for retinal pigmentary maculopathy was a possibility.

The most obvious is the fact that the drug was on the market for over two decades.

Merger of all Elmiron lawsuits

Several manufacturers of Elmiron, a drug for treating interstitial cystitis, are facing a bevy of lawsuits. The drug has caused many side effects, including heartburn, diarrhea, rash, and hair loss. In the process, the drug has made its victims suffer from permanent vision loss.

Some plaintiffs have gone the legal route, while others have opted to settle out of court.

Bellwether MDL trial date postponed

Earlier this year, the Elmiron Eye Damage Lawsuit filed by Maria Windham in the MDL had its bellwether trial date postponed. But the court did not offer any explanation for the postponement.

On July 13, 2022, Judge Martinotti held a status conference. At that time, he also approved the selection of 14 new plaintiff’s attorneys to the Plaintiffs’ Steering Committee.

The judge also finalized key pre-trial dates, including a motions hearing on January 16.The parties will submit a joint proposal for the selection of bellwether cases by April 8.

Section III of CMO 17 establishes rules for the selection of bellwether cases. These cases will set the stage for the eventual global settlement of the MDL.

Optic neuritis and vision loss

Several studies have shown that Elmiron can cause serious vision impairment.

The FDA has not yet issued a safety communication for Elmiron, but it does recommend that users report any vision-related side effects.

Several lawsuits are currently pending against Janssen Pharmaceuticals, the company behind Elmiron. These lawsuits allege that the company failed to adequately warn the public of the risk of permanent vision loss.

Maculopathy

Several studies have linked Elmiron to irreversible visual disease. These include maculopathy, macular degeneration, and other retinal disorders. If you or someone you love has developed one of these symptoms, you may be able to seek compensation through an Elmiron Eye Damage Lawsuit.

One study from the Kaiser Permanente Center for Health Research studied 91 patients. The researchers found that 22 of the participants displayed signs of drug toxicity.

Another study published in November of this year in Ophthalmology compared the effects of Elmiron and pentosan polysulfate sodium (PPS) on pigmentary maculopathy.

Common side effects of Elmiron

Despite the fact that Elmiron is a relatively safe medication, doctors have warned patients about its side effects for decades. A recent study has shown that Elmiron users have a higher risk of eye damage, which can lead to vision problems.

Researchers have linked the drug to retinal maculopathy, a vascular disorder that can cause serious eye damage and vision loss. The retina is a vital part of the body, sending signals to the brain. It also is responsible for recognizing faces and driving.

In some cases, long-term use of Elmiron can lead to retinal damage that is irreversible.

Class-action lawsuits

Earlier this year the Elmiron eye damage class-action lawsuits started to heat up. This is the first major mass tort to see a spike in the number of new plaintiffs since the MDL was established. A record 326 new lawsuits have been filed over the past month alone.

The Elmiron eye damage class-action lawsuits involve a semi-synthetic drug derived from xylan. It is prescribed to patients with interstitial cystitis (IC) to help treat bladder problems. However, it has also been linked to serious eye conditions. It can cause blurred vision, dark spots, and blindness.

The FDA has been evaluating whether to take regulatory action against the drug. Studies suggest that up to one fourth of the patients who took the drug showed signs of toxicity. The rate of toxicity increased with the amount of drug consumed.